Sacklers agree to $6B Purdue bankruptcy settlement; will Civica Rx's plan for low-cost insulin work?

Taking stock of the drug industry, from the lab to the medicine chest  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        Sacklers agree to $6 billion Purdue bankruptcy settlement over opioid crisis By Ed Silverman Douglas Healey/AP The Sackler family members who own Purdue Pharma have agreed to a $6 billion settlement over the company's role in the opioid crisis. Read More STAT+: Civica Rx has an ambitious plan to make low-cost insulin for all Americans. But can it work? By Ed Silverman Alissa Ambrose/STAT Civica Rx announced plans to sell its own versions of three widely prescribed insulin brands. Will it work? Read More STAT+: Washington state moves closer to creating the next prescription drug affordability board By Ed Silverman APStock "More states find they need to take another step toward something that actually helps with affordability,” said policy consultant Jane Horvath. Read More Sponsor content by Evidation Five-step action plan to implement your PGHD strategy A joint FDA-industry meeting identified five key takeaways for organizations seeking to implement the use of person-generated health data (PGHD) to enhance their clinical product development programs. Evidation has written a white paper that describes and expands on these ideas, and draws inspiration from real-world examples that demonstrate the potential of PGHD. Download now. STAT+: With Aduhelm in limbo, Biogen starts laying off employees By Adam Feuerstein and Damian Garde Steven Senn/AP Biogen has said it hopes to save $500 million a year in the process, triggered in part by the disappointing launch of its Alzheimer's drug. Read More STAT+: Awaiting 'definitive' Alzheimer's drug data, Roche and Genentech launch ambitious new study By Damian Garde Adobe The companies are embarking on a four-year trial of their Alzheimer's drug gantenerumab without waiting for data from key ongoing studies. Read More STAT+: Even as it struggles, startup insurer Bright Health deepens its ties to Cigna By Bob Herman Adobe Bright Health is hemorrhaging money, raising questions not only about its future but also about its increasingly close relationship with Cigna Read More Opinion: Turning to social media to get affordable insulin: a clear sign of a broken health care system By Alina Bills Adobe Some people with diabetes must turn to an underground market for affordable insulin and other supplies. They shouldn't have to do that. Read More Opinion: Inappropriate march-in actions would jeopardize public-private partnerships that make lifesaving medicines possible By Mark Reisenauer Adobe Using Bayh-Dole march-in rights to lower a drug's price would set a troubling precedent and jeopardize new drug discovery and development. Read More Thursday, March 3, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser